Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blood pressure and metabolic effects of nebivolol compared with hydrochlorothiazide and placebo in hypertensive patients with impaired glucose tolerance or impaired fasting glucose

Next Previous
Trial Profile

Blood pressure and metabolic effects of nebivolol compared with hydrochlorothiazide and placebo in hypertensive patients with impaired glucose tolerance or impaired fasting glucose

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nebivolol (Primary) ; Hydrochlorothiazide; Lisinopril; Losartan
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Sponsors Forest Laboratories

Most Recent Events

  • 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
  • 22 Sep 2010 Actual end date added to 1 Jul 2010 as reported by ClinicalTrials.gov.
  • 22 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top